| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Cybin Inc.$7.21
-0.03 (-0.42%)
D 39Pipeline Score Undervalued Pharma · Clinical
Market Cap
1.39 M
EPS
-4.59
P/E Ratio
-
Value Trade
2.27 M
-6.02 %
Week
-6.59 %
1 Month
-31.78 %
3 Month
-20 %
6 Month
-91.95 %
5 Year
-37.1 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
709.06 K
52 Week Range
4.15 - 9.83
% held by Insiders
21.45 %
% held by Institutions
29.79 %
Enterprise Value
-193.39 M
Total Shares
50.07 M
Short %
5.98 %
Float Shares
50.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cybin Inc.
61Total events
2Upcoming
11Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▲Enrollment MilestoneHLP003Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D39
Pipeline Score $20M
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored14.4x
rNPV / MCap Top 55%
Micro Cap (rank 412 of 913)
Percentile RankCybin Inc. faces pipeline headwinds (39/100), with $1.6B risk-adjusted pipeline value, led by CYB003 in Major Depressive Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYB003 Small molecule | Major Depressive Disorder (MDD) | Phase 3 | NCT06793397 | 49% | $1.3B | RECRUITING | 330 | FAST | B (70) | May 8, 2027 | MODERATE_RISK | LOW Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HLP004 | Generalized Anxiety Disorder | Phase 2 | 2026-03-05 | mean improvement of 10.4 points on the Hamilton Anxiety Rating Scale; 67% of participants responding positively after six months; 39% of patients were in remission Read More | Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder Read More | |
HLP004 | Generalized Anxiety Disorder | Phase 2 | 2026-03-05 | mean improvement of 10.4 points on the Hamilton Anxiety Rating Scale; 67% of participants responding positively after six months; 39% of patients were in remission Read More | Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder Read More | |
HLP004 | Generalized Anxiety Disorder | Phase 2 | 2026-03-05 | mean improvement of 10.4 points on the Hamilton Anxiety Rating Scale; 67% of participants responding positively after six months; 39% of patients were in remission Read More | Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HELP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HELP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HELP▲ +10.5%on this news
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Helus Pharma's Phase 3 trial for HLP003, aimed at treating major depressive disorder, has exceeded 86% enrollment, maintaining its timeline for topline data in Q4 2026. The drug has received FDA Breakthrough Therapy Designation, indicating its potential as a transformative treatment. However, the Phase 2 results remain unverified by the FDA, and the trial's outcomes are uncertain.
Read more →HELP▲ +18.3%on this news· ran to +30% by day 3shared move
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma has successfully closed a $50 million underwritten offering of 10,309,280 common shares at $4.85 each. The proceeds will be used to advance its drug programs, particularly HLP003 for major depressive disorder, which is expected to have Phase 3 data by late 2026. The offering was managed by Cantor and Barclays, among others.
Read more →HELPHelus Pharma™ Announces US$50 Million Underwritten Offering
Helus Pharma has announced a $50 million underwritten offering of common shares at $4.85 each, expected to close on June 25, 2026. The proceeds will support the development of its serotonergic agonists, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder. The offering is subject to regulatory approvals and customary closing conditions.
Read more →HELPHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
Helus Pharma is set to participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference on June 15-16, 2026. Chief Medical Officer Amir Inamdar will engage in a fireside chat available on demand. The company focuses on developing novel serotonergic agonists aimed at treating mental health conditions, with HLP003 in Phase 3 and HLP004 in Phase 2 clinical trials.
Read more →HELPHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Helus Pharma will have its Interim CEO, Eric So, participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The event will be webcast live, allowing wider access to the company's insights. Helus Pharma is focused on developing novel serotonergic agonists for mental health conditions.
Read more →HELP▲ +8.1%on this news
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
Helus Pharma has partnered with TARA Mind to enhance recruitment for its Phase 3 clinical trial of HLP003, aimed at treating Major Depressive Disorder among veterans. This collaboration aligns with a recent Executive Order aimed at improving mental health treatments for veterans. The partnership seeks to increase awareness and access to clinical trials within veteran communities.
Read more →HELP▲ +8.1%on this news
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Helus Pharma will participate in the 29th Annual Milken Institute Global Conference, with Interim CEO Eric So speaking on a panel about health innovation. The conference is set for May 3-6, 2026, in Los Angeles. Helus Pharma focuses on developing novel serotonergic agonists to address mental health issues, with HLP003 in Phase 3 for major depressive disorder.
Read more →HELPHelus Pharma Partners with TARA Mind to Advance Veteran Mental Health
Helus Pharma has partnered with TARA Mind to enhance recruitment for its HLP003 Phase 3 clinical trial targeting Major Depressive Disorder in veterans. This collaboration follows a recent Executive Order aimed at improving mental health treatment access for veterans. The partnership seeks to leverage TARA Mind's networks to increase awareness and participation in clinical research.
Read more →HELPHelus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Helus Pharma has strengthened its Scientific Advisory Board with the addition of Dr. Robert Langer and Dr. Stephen Brannan, both recognized leaders in translational science and clinical development. This move is aimed at advancing the company's pipeline of novel serotonergic agonists, particularly for major depressive disorder and generalized anxiety disorder. The board, chaired by Dr. Freda Lewis-Hall, will guide the company in its commitment to rigorous drug development.
Read more →HELPHelus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
Helus Pharma has expressed support for a White House Executive Order aimed at enhancing research and regulatory pathways for psychedelic treatments targeting serious mental health conditions. The order includes initiatives such as prioritizing FDA reviews for breakthrough therapies and increasing federal funding for state programs. Helus Pharma's lead program, HLP003, is in Phase 3 development for major depressive disorder and has received Breakthrough Therapy designation.
Read more →HELPHelus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
Helus Pharma has appointed Dr. Ken Kramer as Senior Vice President of Medical Affairs. With over 25 years of experience in neuroscience, Dr. Kramer is expected to strengthen the company's medical capabilities and enhance engagement with the scientific community. His previous roles include leadership positions at Bristol Myers Squibb and Karuna Therapeutics, where he successfully launched new treatments.
Read more →HELP▼ -33.9%on this news
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Helus Pharma announced positive topline results from a Phase 2 study of HLP004 for generalized anxiety disorder (GAD). The study showed a significant reduction in anxiety symptoms, with a mean improvement of 10.4 points on the Hamilton Anxiety Rating Scale. The treatment demonstrated durable effects, with 67% of participants responding positively after six months. HLP004 was well-tolerated, with no serious adverse events recorded.
Read more →HELP▼ -33.9%on this newsshared move
Filed by newsfilecorp.com Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder Statistically significant (p 0.0001) and clinically meaningful i
Helus Pharma announced positive topline results from a Phase 2 study of HLP004 for treating generalized anxiety disorder (GAD). The study showed a statistically significant improvement in anxiety symptoms, with a mean reduction of over 10 points on the Hamilton Anxiety Rating Scale after six weeks. The treatment was well-tolerated and demonstrated durable effects, with a considerable percentage of patients achieving remission after six months. This promising data underscores the potential of HLP004 as a novel adjunctive therapy for individuals with GAD who have not responded to traditional treatments.
Read more →HELP▲ +9.5%on this news
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
Helus Pharma has appointed Dr. Freda Lewis-Hall as a member of its Board of Directors and Chair of the Scientific Advisory Committee. Dr. Lewis-Hall brings over 40 years of experience in clinical care and biopharmaceutical leadership, having previously served as Chief Medical Officer at Pfizer. Her expertise will support Helus Pharma's development of novel serotonergic agonists for mental health disorders.
Read more →HELP▲ +11%on this news
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Helus Pharma announced the publication of a Phase 2a trial in Nature Medicine, showing that SPL026 significantly reduced depressive symptoms in patients with major depressive disorder. The study met its primary endpoint with effects lasting up to six months. The treatment was well tolerated, indicating its potential as a viable option for depression management.
Read more →HELPHELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
HELUS Pharma reported its financial results for Q3 FY 2026, highlighting a cash position of $195 million. The company is advancing its clinical programs, including HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder. Upcoming milestones include topline data readouts expected in Q1 2026.
Read more →HELPHelus Pharma แต่งตั้ง Michael Cola ดำรงตำแหน่งประธานเจ้าหน้าที่บริหารเพื่อนำบริษัทสู่ก้าวย่างถัดไปของการขยายขนาดและการดำเนินงาน
Helus Pharma has announced significant advancements in its pipeline of novel serotonergic agonists, with multiple product launches expected by 2026. Under the leadership of CEO Michael Cola, the company aims to enhance its market position in the CNS sector. The strategic direction emphasizes innovation and growth, positioning Helus for future success.
Read more →HELPHelus Pharma ernennt Michael Cola zum Chief Executive Officer für die Leitung der nächsten Skalierungs- und Durchführungsphase
Helus Pharma has appointed Michael Cola as Chief Executive Officer to lead the company through its next growth phase. Cola's extensive background in neuroscience and commercialization is expected to drive the advancement of Helus' innovative therapies for mental health. The company is approaching key clinical milestones, including Phase II data for HLP004 and Phase III data for HLP003 in 2026.
Read more →HELPHelus Pharma nombra a Michael Cola como director ejecutivo para liderar su próxima etapa de crecimiento y ejecución
Helus Pharma has appointed Michael Cola as CEO to lead the company's next growth phase. This decision comes as Helus advances its innovative mental health therapies, including the upcoming Phase II data for HLP004 and Phase III data for HLP003. Cola brings over 30 years of experience in neuroscience and pharmaceutical development, positioning Helus for significant advancements in mental health treatment.
Read more →HELPHelus Pharma Nomeia Michael Cola como Diretor Executivo para Liderar a Próxima Fase de Escala e Execução
Helus Pharma has appointed Michael Cola as CEO to lead the company's next growth phase. Cola brings over 30 years of experience in neuroscience and pharmaceutical development. The company is focused on advancing its pipeline of novel serotonin agonists aimed at treating severe mental health disorders, with key clinical data expected soon.
Read more →HELPHelus Pharma Melantik Michael Cola sebagai Ketua Pegawai Eksekutif untuk Menerajui Fasa Seterusnya Pertumbuhan dan Pelaksanaan
Helus Pharma has appointed Michael Cola as CEO to lead the company through its next growth phase. Cola's extensive background in neuroscience and pharmaceuticals positions him well to guide Helus as it advances its mental health therapies. The company expects to release Phase 2 data for HLP004 and Phase 3 data for HLP003 in the near future.
Read more →HELPHelus Pharma nomme Michael Cola au poste de directeur général pour piloter la prochaine phase de développement et d’exécution
Helus Pharma has appointed Michael Cola as CEO to lead its next development phase. This decision comes as the company prepares to advance its mental health treatments, including upcoming Phase 2 data for HLP004 and Phase 3 data for HLP003. Cola's extensive experience in neuroscience and global commercialization is expected to drive the company's growth and innovation in mental health therapies.
Read more →HELPヘラス・ファーマ、次段階の規模拡大と事業実行主導に向けてマイケル・コーラを最高経営責任者に任命
Helus Pharma has announced the appointment of Michael Cola as CEO, aiming to strengthen its leadership in the development of innovative therapies for central nervous system disorders. The company is set to advance its clinical trials for HLP003 and HLP004, with significant milestones expected in 2026. This strategic move is part of Helus Pharma's broader goal to enhance its market position and address critical health challenges.
Read more →HELPHelus Pharma 委任 Michael Cola 為行政總裁，領導公司下一階段的擴張與執行
Helus Pharma has appointed Michael Cola as the new CEO, effective immediately. Cola brings extensive experience in the pharmaceutical industry, having previously held leadership roles in major companies. Under his leadership, Helus aims to advance its innovative pipeline, focusing on new treatments for mental health disorders. The company is set to progress its product candidates HLP003 and HLP004 in the coming years.
Read more →HELPHelus Pharma Mengangkat Michael Cola sebagai Chief Executive Officer untuk Memimpin Fase Peningkatan Skala dan Eksekusi Berikutnya
Helus Pharma has appointed Michael Cola as the new CEO to lead the company's next growth phase. Cola's extensive experience in neuroscience and drug commercialization is expected to enhance Helus's efforts in developing innovative therapies for mental health disorders. The company is preparing for significant clinical data releases in the coming quarters, aiming to address unmet medical needs.
Read more →HELPHelus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Helus Pharma has appointed Michael Cola as its new CEO, effective immediately. His leadership is expected to guide the company through critical clinical milestones, including the upcoming Phase 2 and Phase 3 data releases for its novel serotonergic agonists. With extensive experience in neuroscience and commercialization, Cola aims to enhance the development of Helus's mental health therapies.
Read more →HELPFiled by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (the " Company ") 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material Change
Cybin Inc. announced the launch of an at-the-market equity program allowing it to issue and sell up to $100 million of common shares. This initiative aims to provide the company with additional capital for growth opportunities and working capital initiatives. Sales will be made under specified market conditions via agents, and there is no obligation for the company to sell any shares. The program is effective until October 17, 2027, or until the maximum amount is reached.
Read more →HELPFiled by newsfilecorp.com Cybin Inc. Shares of Common Stock
Cybin Inc. has entered into an equity distribution agreement with Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co. to issue and sell common shares. The company can raise up to $100 million through this initiative, offering flexibility in timing and amounts for sales. The arrangement allows for potential enhancements to the company's capital base and strategic financial positioning as they navigate market conditions.
Read more →HELPFiled by newsfilecorp.com Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
Cybin Inc. has filed a Securities Purchase Agreement dated October 28, 2025, outlining the sale of its securities to various purchasers. The agreement specifies its terms, the applicable laws, and the definitions of key terms such as 'Company,' 'Purchaser,' and others relevant to the transaction. The offering will be conducted under Canadian and U.S. securities laws, ensuring compliance with relevant regulations. The closing of the purchase is anticipated to occur on October 31, 2025, pending the satisfaction of certain conditions.
Read more →HELPFiled by newsfilecorp.com
AIRD & BERLIS LLP has consented to the inclusion of their firm name in the Prospectus Supplements associated with the registration statement on Form F-10 filed with the U.S. SEC. This consent also extends to the mention of their advice regarding the enforcement of civil liabilities for U.S. investors. The filing is part of the company's efforts to comply with regulatory requirements.
Read more →HELPFiled by newsfilecorp.com Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - 100% of participants were responsive to treatment and 71% of
Cybin has announced encouraging results from its Phase 2 trial for CYB003, a treatment for major depressive disorder (MDD). The data reveals that 100% of participants responded positively to the treatment and 71% remained in remission after 12 months, following just two doses. The treatment shows a significant mean reduction of 23 points on the Montgomery-Asberg Depression Rating Scale from baseline. The Phase 3 PARADIGM program for CYB003 has been initiated, aiming to further evaluate its safety and efficacy in a broader population.
Read more →HELPFiled by newsfilecorp.com SMALL PHARMA INC. (formerly, Unilock Capital Corp.) Consolidated Financial Statements Years ended
Small Pharma Inc. (formerly Unilock Capital Corp.) has released its consolidated financial statements for the years ended February 28, 2023, and 2022. The independent auditor's report confirms that the financial statements present fairly, in all material respects, the company's financial position and performance. Importantly, no significant issues were noted during the audit process, which was conducted in compliance with prevailing auditing standards. The financial results and operations reflect a thorough assessment of the company's capability to continue as a going concern.
Read more →HELPFiled by newsfilecorp.com SMALL PHARMA INC. Interim Condensed Consolidated Financial Statements Three months ended
Small Pharma Inc. released its interim condensed consolidated financial statements for the three months ended May 31, 2023, reporting a net loss of 5,643,667 CAD. This represents a slight improvement over the net loss of 5,781,704 CAD recorded during the same period in 2022. However, total assets declined from 20,983,819 CAD to 15,241,553 CAD, indicating financial difficulties. The financial report highlights ongoing expenses in areas such as research and development, while the company has yet to generate revenue.
Read more →HELPCybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023 - Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an...
Cybin Inc. announced positive interim results from its Phase 2 trial of CYB003, showing a significant reduction in major depressive disorder symptoms after a single 12mg dose. The mean reduction in the Montgomery-Asberg Depression Rating Scale score was 14.08 points compared to placebo. The trial demonstrated a favorable safety profile, with no serious adverse events reported. Full topline data is expected in Q4 2023.
Read more →HELPCybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder - Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly - - Phase 2...
Cybin Inc. has successfully completed dosing in Cohort 5 of its Phase 2 trial for CYB003, a treatment for major depressive disorder, with no reported safety issues. Recruitment for Cohort 6 is underway, and topline efficacy data is anticipated later this year. The company plans to submit Phase 1/2a data to the FDA following the data readout.
Read more →HELPCybin Provides 2021 Year End Summary TORONTO, CANADA
Cybin Provides 2021 Year End Summary TORONTO, CANADA December 22, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM is pleased to provide a year-end summary of its major mi
Read more →HELPCybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference TORONTO, CANADA
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference TORONTO, CANADA December 21, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing P
Read more →HELPCybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders - Expands intellectual property portfolio and strengthens posi
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders - Expands intellectual property portfolio and strengthens position as leading innovator in developing putative psychede
Read more →HELPCybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder TORONTO, CANADA
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder TORONTO, CANADA December 8, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cy
Read more →HELPCybin to Present at the Stifel GMP 2 nd Annual Future of Healthcare Conference on
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021 TORONTO, CANADA December 1, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeut
Read more →HELPCybin to Participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference on
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021 TORONTO, CANADA November 29, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therape
Read more →HELPCybin Announces Additional Adelia Milestone Achievements TORONTO, CANADA
Cybin Announces Additional Adelia Milestone Achievements TORONTO, CANADA November 26, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing Psychedelics to Therapeutics , is pleased to announce that Adelia Thera
Read more →HELPCybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities TORONTO, CANADA
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved TORONTO, CANADA November 23, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeuti
Read more →HELPCybin to Present at the Jefferies London Healthcare Conference TORONTO, CANADA
Cybin to Present at the Jefferies London Healthcare Conference TORONTO, CANADA November 11, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM is pleased to announce that Do
Read more →HELPCybin to Announce Second Quarter FY2021 Financial Results and Business Update on
Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021 TORONTO, CANADA November 9, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeuti
Read more →HELPCybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health Comparative CYB003 pre-clinical data on the Company s deuterated psilocybin analog may have wi
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health Comparative CYB003 pre-clinical data on the Company s deuterated psilocybin analog may have wide-reaching implications for the treatment of Major Depre
Read more →HELPCybin Granted DEA Schedule I Manufacturing License The Company Also Welcomes Leah Gibson as its New Vice President of Investor Relations TORONTO, CANADA
Cybin Granted DEA Schedule I Manufacturing License The Company Also Welcomes Leah Gibson as its New Vice President of Investor Relations CANADA November 4, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progress
Read more →HELPCybin Hosting Research and Development Briefing on
Cybin Hosting Research and Development Briefing on November 8, 2021 Breakthrough pre-clinical, research findings to be released show therapeutic advancements on the data-driven evolution of psychedelic November 2, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the
Read more →HELPCybin Announces Launch of EMBARK Psychedelic Facilitator Training Program TORONTO, CANADA
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program TORONTO, CANADA October 28, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today announced the launch o
Read more →HELPCybin Announces FDA Investigational New Drug Authorization of Cybin s Sponsored Feasibility Study using Kernel Flow Technology TORONTO, CANADA
Cybin Announces FDA Investigational New Drug Authorization of Cybin s Sponsored Feasibility Study using Kernel Flow Technology TORONTO, CANADA October 26, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing p
Read more →HELPCybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies --The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, sh
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies --The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media-- TORONTO, CANADA Oc
Read more →HELPCybin Files an International Patent Application Covering Psychedelic Delivery Methods TORONTO, CANADA
Cybin Files an International Patent Application Covering Psychedelic Delivery Methods TORONTO, CANADA Oct 12, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today announced that
Read more →HELPCybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development Promotion of Certain Members of Management Team and Engagement
Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development Promotion of Certain Members of Management Team and Engagement with a Capital Markets Communications Firm TORONTO, CAN
Read more →HELPCybin to Present at Upcoming Cantor and Benzinga Investor Conferences TORONTO, CANADA
Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences TORONTO, CANADA September 27, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysd
Read more →HELPCybin to Present at the H.C. Wainwright 23 rd Annual Global Investment Conference on September 13 th TORONTO, CANADA
Cybin to Present at the H.C. Wainwright 23rd Annual Investment Conference on September 13th TORONTO, CANADA September 9, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today ann
Read more →HELPCybin Files Two Additional International Patent Applications in Support of the Company s Research Phase Programs TORONTO, CANADA
Cybin Files Two Additional International Patent Applications in Support of the Company s Research Phase Programs TORONTO, CANADA August 19, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic ther
Read more →HELPCybin Announces Election of Theresa Firestone as Director, Results of Shareholders Meeting and Adoption of Shareholder Rights Plan TORONTO, CANADA
Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders Meeting and Adoption of Shareholder Rights Plan TORONTO, CANADA August 16, 2021 Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ( Cybin or the Company ), a biotechnology company focused on psychedeli
Read more →HELPCybin to Present at Canaccord Genuity s 41 st Annual Growth Conference on August 10 th TORONTO, CANADA
Cybin to Present at Canaccord Genuity s 41st Annual Growth Conference on August 10th TORONTO, CANADA August 9, 2021 Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Dr
Read more →HELPCybin to Commence Trading on the NYSE American on August 5 TORONTO, CANADA
Cybin to Commence Trading on the NYSE American on August 5 TORONTO, CANADA August 4, 2021 Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ( Cybin or the Company ), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for
Read more →HELPFORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Cybin Inc. (formerly, Clarmin Explorations Inc.) (the Company ) 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Item 2. Date of Material
MATERIAL CHANGE REPORT Name and Address of Company Cybin Inc. (formerly, Clarmin Explorations Inc.) (the Company ) 100 King Street West, Suite 5600 Item 2. Date of Material Change Item 3. News Release News releases with respect to the material change were disseminated by th
Read more →Competitive Position
How HELP ranks across every disease it competes inCompetitive Position is a premium feature
See how HELP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial